Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjogren's syndrome

Imagem de Miniatura
Arquivos
art_PASOTO_Lupus_anticoagulant_a_marker_for_stroke_and_venous_2012.PDF (179.83 KB)
Citações na Scopus
44
Tipo de produção
article
Data de publicação
2012
Editora
SPRINGER LONDON LTD
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
LEVY NETO, Mauricio
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
CLINICAL RHEUMATOLOGY, v.31, n.9, p.1331-1338, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Antiphospholipid antibodies (aPL) and antiphospholipid syndrome (APS) have been described in primary Sjogren's syndrome (pSS) with controversial findings regarding aPL prevalence and their association with thrombotic events. We evaluated 100 consecutive pSS patients (American-European criteria) and 89 age-gender-ethnicity-matched healthy controls for IgG/IgM anticardiolipin (aCL), IgG/IgM anti-beta2-glycoprotein-I (a beta 2GPI), and lupus anticoagulant (LA) (positivity according to APS Sydney's criteria). Clinical analysis followed standardized interview and physical examination assessing thrombotic and nonthrombotic APS manifestations and thrombosis risk factors. aPLs were detected in 16 % patients and 5.6 % controls (p = 0.035). LA was the most common aPL in patients (9 %), followed by a beta 2GPI (5 %) and aCL (4 %). Thrombotic events occurred in five patients [stroke in two, myocardial infarction in one and deep-vein thrombosis (DVT) in four], but in none of controls (p = 0.061). Mean age at time of stroke was 35 years. Three patients with thrombotic events (including the two with stroke) had APS (Sydney's criteria) and were positive exclusively for LA. Comparison of patients with (n = 16) and without (n = 84) aPL revealed similar mean age, female predominance, and ethnicity (p > =0.387). Frequencies of livedo reticularis (25 vs. 4.8 %, p = 0.021), stroke (12.5 vs. 0 %, p = 0.024), and DVT (18.8 vs. 1.2 %, p = 0.013) were significantly higher in APL + patients. Conversely, frequencies of hypertension, dyslipidemia, diabetes, obesity, smoking, sedentarism, and hormonal contraception were similar in patients with or without aPL (p a parts per thousand yenaEuro parts per thousand 0.253). Our study identified LA as an important marker for APS in pSS, particularly for stroke in young patients, warranting routine evaluation of these antibodies and rigorous intervention in modifiable risk factors.
Palavras-chave
Antiphospholipid antibodies, Antiphospholipid syndrome, Deep-vein thrombosis, Lupus anticoagulant, Primary Sjogren's syndrome, Stroke
URI
https://observatorio.fm.usp.br/handle/OPI/505
Referências
  1. Amarasena R, 2007, CLIN MED, V7, P53
  2. ASHERSON RA, 1992, ANN RHEUM DIS, V51, P495, DOI 10.1136/ard.51.4.495
  3. Bakker AJ, 2003, CLIN CHEM LAB MED, V41, P85, DOI 10.1515/CCLM.2003.015
  4. Biggioggero M, 2010, AUTOIMMUN REV, V9, pA299, DOI 10.1016/j.autrev.2009.11.013
  5. Cervera R, 1997, CLIN EXP RHEUMATOL, V15, P361
  6. Delalande S, 2004, MEDICINE, V83, P280, DOI 10.1097/01.md.0000141099.53742.16
  7. ESPARZA RH, 1985, J RHEUMATOL, V12, P1109
  8. Fauchais AL, 2004, LUPUS, V13, P245, DOI 10.1191/0961203304lu1006oa
  9. Galanaud JP, 2011, CURR OPIN PULM MED, V17, P387, DOI 10.1097/MCP.0b013e328349a9e3
  10. Garcia-Carrasco M, 2002, MEDICINE, V81, P270, DOI 10.1097/01.md.0000024210.15761.9a
  11. Goeldner I, 2010, RHEUMATOLOGY, V49, P1590, DOI 10.1093/rheumatology/keq134
  12. Haga HJ, 2008, SCAND J RHEUMATOL, V37, P127, DOI 10.1080/03009740701716843
  13. He J, 2011, RHEUMATOLOGY, V50, P879, DOI 10.1093/rheumatology/keq420
  14. JEDRYKAGORAL A, 1992, ANN RHEUM DIS, V51, P889, DOI 10.1136/ard.51.7.889
  15. Juby AG, 1998, CLIN INVEST MED, V21, P4
  16. Katayama Y, 2000, INTERNAL MED, V39, P6
  17. Mahler M., 2005, Clinical and Diagnostic Laboratory Immunology, V12, P107, DOI 10.1128/CDLI.12.1.107-113.2005
  18. Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x
  19. Palomo I, 2009, CLIN EXP RHEUMATOL, V27, P668
  20. Petri M, 2000, J AUTOIMMUN, V15, P145, DOI 10.1006/jaut.2000.0409
  21. Pierangeli SS, 2005, CLIN CHIM ACTA, V357, P17, DOI 10.1016/j.cccn.2005.02.002
  22. Ramirez M, 2009, MED CLIN-BARCELONA, V133, P349, DOI 10.1016/j.medcli.2008.12.027
  23. Ramos-Casals M, 2006, SEMIN ARTHRITIS RHEU, V35, P312, DOI 10.1016/j.semathrit.2005.12.004
  24. Reber G, 2004, J THROMB HAEMOST, V2, P1860, DOI 10.1111/j.1538-7836.2004.00910.x
  25. Routsias JG, 2007, CLIN REV ALLERG IMMU, V32, P238, DOI 10.1007/s12016-007-8003-8
  26. Ruiz-Tiscar JL, 2005, ANN NY ACAD SCI, V1050, P210, DOI 10.1196/annals.1313.022
  27. Sanz J, 2011, J AM COLL CARDIOL, V58, P779, DOI 10.1016/j.jacc.2011.03.052
  28. Seror R, 2010, ANN RHEUM DIS, V69, P1103, DOI 10.1136/ard.2009.110619
  29. SHI W, 1990, AUST NZ J MED, V20, P231, DOI 10.1111/j.1445-5994.1990.tb01025.x
  30. Tektonidou MG, 2009, ARTHRIT RHEUM-ARTHR, V61, P29, DOI 10.1002/art.24232
  31. Theander E, 2008, RHEUM DIS CLIN N AM, V34, P935, DOI 10.1016/j.rdc.2008.08.009
  32. Tzioufas AG, 2007, BEST PRACT RES CL RH, V21, P989, DOI 10.1016/j.berh.2007.09.001
  33. Ulvestad E, 2000, SCAND J RHEUMATOL, V29, P330
  34. Urbanus RT, 2009, LANCET NEUROL, V8, P998, DOI 10.1016/S1474-4422(09)70239-X
  35. Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554
  36. Wielosz Ewa, 2007, Pol Arch Med Wewn, V117 Suppl, P76
  37. Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
  38. Wisloff F, 2002, THROMB RES, V108, P263, DOI 10.1016/S0049-3848(02)00400-0

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/17